| Title | Wnt therapy for bone loss: golden goose or Trojan horse? | | Author(s) | Enders GH | | Institution | Department of Medicine, Epigenetics and Progenitor Cell Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. greg.enders@fccc.edu | | Source | J Clin Invest 2009 Apr; 119(4):758-60. | | MeSH | Adaptor Proteins, Signal Transducing
Animals
Extracellular Matrix Proteins
Gene Silencing
Genes, Tumor Suppressor
Humans
Intercellular Signaling Peptides and Proteins
Mice
Models, Biological
Osteoporosis
Osteosarcoma
Repressor Proteins
Signal Transduction
Wnt Proteins
| | Abstract | The Wnt pathway has been found to play a role in the development of many tissues and to spur growth and differentiation of adult osteoblasts, sparking interest in its potential clinical application for bone growth. However, when deregulated, this pathway can be oncogenic in some tissues. In this issue of the JCI, Kansara and colleagues reveal that Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcomas and that its absence augments osteosarcoma formation in mice (see the related article beginning on page 837). These observations suggest the need for caution in stimulating the Wnt pathway for therapeutic bone growth. | | Language | eng | | Pub Type(s) | Comment
Journal Article
Research Support, N.I.H., Extramural
| | PubMed ID | 19348043 |
|
